# Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that blocking the HPGDS enzyme can be a viable way to improve patients’ response to immunotherapy since the activity of this enzyme contributes to immunotherapy resistance. This approach can also increase immunotherapy response in other types of cancer with similar attributes to those of melanoma.

 Given that this research was preclinical, its findings can only hold concrete promise if they are replicated in clinical studies. There’s still plenty to do before this new treatment approach can be tested on human subjects. In the meantime, immune-oncology companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) that already have new…

 Read More>>

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/blocking-an-enzyme-in-melanoma-patients-could-overcome-resistance-to-immunotherapy/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/breakthrough-research-blocking-enzyme-to-improve-immunotherapy-response-in-melanoma-patients/8b30107809cb33670fc5a3f46067ab9f) 

 



[Reddit Post](https://www.reddit.com/r/newsramp/comments/1k03ivu/breakthrough_research_blocking_enzyme_to_improve/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/254/15/sage0M_c.webp)